Aim To evaluate the demographic and clinical data of fifty two patients with the diagnosis of ulcerative colitis. Methods A total of 52 patients diagnosed with ulcerative colitis by clinical, endoscopical and histopathological evaluations were included the study. Demographic data, colon involvement site of the disease and disease severity were examined from the patients' records. The patients were divided into groups according to the Baron grading system. Results Distribution of patients according to the colon involvement site was: 10 (9.2%) rectal, 16 (30.8%) rectosigmoid, 13 (25%) left sided, 10 (19.2%) extensive colitis and 3 (5.8%) pancolitis. According to colon involvement sites and Baron classification the results were: five (9.6 %), two (3.8%) and three (5.7%) patients with ulcerative proctitis were at grade 1, 2 and 3, respectively. Two (3.8%), six (11.5 %), six (11.5 %) and two (3.8%) patients with rectosigmoid ulcerative colitis were at grade 0, 1, 2 and 3, respectively. Four (7.6 %), five (9.6%) and four (7.6%) patients with left sided ulcerative colitis were at grade 1, 2, and 3, respectively. One (1.9 %), three (5.7%), and six (11.5 %) patients with extensive ulcerative colitis were at grade 1, 2 and 3, respectively. All three (5.7%) patients with pancolitis were at grade 3 (p=0.11) Conclusion The ratio of pancolitis is found to be lower in our series. There was no statistically significant difference among the genders according to the age, involvement site and the severity of the disease as well as according to the colon involvement sites and grading.
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;1713–25.
2.
Torpy J, Lynm C, Golub R. Ulcerative Colitis. JAMA. 2012;104.
3.
Thoreson R, Cullen J. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. 2007;575–85.
4.
Moller F, Andersen V, Wohlfahrt J, Jess. Familial risk of inflammatory bowel disease: a populationbased cohort study 1977-2011. Am J Gastroenterol. 2015;564–71.
5.
Andreu M, Márquez L, Domènech E, Gisbert J, García V, Marín-Jiménez I, et al. Disease severity in familial cases of IBD. J Crohns Colitis. 2014;234–9.
6.
Orholm M, Munkholm P, Langholz E, Nielsen O, Sørensen T, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;84–8.
7.
Li J, Wang F, Zhang H, Sheng J, Yan W, Ma M, et al. Coticosteroid therapy in ulcerative colitis: clinical response and predictors. World J Gastroenterol. 2015;3005–15.
8.
Wong S, Ng S. What can we learn from inflammatory bowel disease in developing countries? Current Gastroenterol Rep. 2015;313.
9.
Jiang X, Cui H. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol. 2002;158–61.
10.
Gong W, Lv N, Wangetal B. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012;503–7.
11.
Ozin Y, Kılıç M, Nadir I, Cakal B, Disibeyaz S, Arhan M, et al. Clinical features of ulcerative colitis and Crohn’ s disease in Turkey. J Gastrointestin Liver Dis. 2009;157–62.
12.
Ma AS, Kalaoui M, Patty I, Hasan F, Khajah A, Al-Nakib B. Ulcerative colitis in Kuwait: a review of 90 cases. Digestion. 2003;218–24.
13.
Karlén P, Löfberg R, Broström O, Leijonmarck C, Hellers G, Persson P. Increased risk of cancer in ulcerative colitis: A population-based cohort study. Am J gastroenterol. 1999;1047–52.
14.
Ekbom A, Helmick C, Zack M, Ho A. Ulcerative colitis and colorectal cancer: a population -based study. N Engl J Med. 1990;357–9.
15.
Tahara T, Inoue N, Hisamatsu T, Kashiwagi K, Kanai T, Watanabe M, et al. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol. 2005;710–5.
16.
Karaman A, Hamurcu Z, Donmez H, Bitken N, Karaman H, Baskol M, et al. Investigation of genome instability in exfoliated colonic epithelial cells and mitogenstimulated lymphocytes of patients with ulcerative colitis. Digestion. 2012;228–35.
17.
Regueiro M. Diagnosis and treatment of ulcerative proctitis. J Clinic Gastroenterol. 2004;733–40.
18.
Shirazi K, Somi M, Bafandeh Y, Saremi F, Mylanchy N, Rezaeifar P, et al. Epidemiological and clinical characteristics of inflammatory bowel disease in patients from northwestern iran. Middle East J Dig Dis. 2013;86–92.
19.
Balai H, Asadzadeh A, Aghdaei H, Farnood A, Habibi M, Mafi A, et al. Time trend analysis and demographic features of inflammatory bowel disease in Tehran. Gastroenterol Hepatol Bed Bench. 2015;253–61.
20.
Björck S, Dahiström A, Ahlman H. Treatment of distal colitis with local anaesthetic agents. Pharmacol Toxicol. 2002;173–80.
21.
Ozdil S, Akyüz F, Pinarbasi B, Demir K, Karaca C, Boztas G, et al. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission? Hepatogastroenterology. 2004;768–70.
22.
Kühbacher T, Scheiber S, Fölsch U. Ulcerative colitis: conservative management and long term effects. Langenbecks Arch Surg. 2004;350–3.
23.
Su C, Lichtenstein G. Diagnosis of Crohn’s disease: A wolf in sheep’s clothing? Am J Gastroenterol. 2000;3345–50.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
